Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26975070 | 0.81 | AKT1 (0.38) | MAP4K4ROCK2LIMK1LIMK2AKT1 | |
| SCHEMBL30829000 | 0.79 | RIPK1 (0.32) | LRRK2ROCK2LIMK1LIMK2CYP2C19 | |
| SCHEMBL26646934 | 0.79 | RIPK1 (0.32) | LRRK2ROCK2LIMK1LIMK2CYP2C19 | |
| SCHEMBL6119348 | 0.77 | AKT1 (0.38) | LRRK2MAP3K12AKT1DPP4 | |
| SCHEMBL792633 | 0.77 | EGLN2 (0.40) | LRRK2ROCK2LIMK1LIMK2AKT1 | |
| SCHEMBL23294851 | 0.77 | LRRK2 (0.41) | LRRK2AKT1DPP4 | |
| SCHEMBL12650637 | 0.77 | HRH3 (0.51) | — | |
| SCHEMBL13279680 | 0.75 | OPRD1 (0.47) | LRRK2MAP4K4PDE10A | |
| SCHEMBL31508129 | 0.75 | PDE10A (0.41) | LRRK2MAP4K4MAP3K12PDE10A | |
| SCHEMBL10187294 | 0.75 | SMPD3 (0.41) | AKT1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12312339-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-117794529-A | POLO-like kinase 4 inhibitors | 欧瑞克制药公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4337198-A1 | POLO LIKE KINASE 4 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2022240876-A1 | POLO LIKE KINASE 4 INHIBITORS | ORIC PHARMACEUTICALS, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| WO-2012001107-A1 | PIPERIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124426-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | LRRK2 1231/4885MAP4K4 26/4885MAP3K12 102/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | LRRK2 1231/4885MAP4K4 26/4885MAP3K12 102/4885 |
| US-20230365537-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | LRRK2 1231/4885MAP4K4 26/4885MAP3K12 102/4885 |
| US-12312339-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | LRRK2 1231/4885MAP4K4 26/4885MAP3K12 102/4885 |
| US-20240270722-A1 | POLO LIKE KINASE 4 INHIBITORS | PLK4, PLK2, PLK3 | LRRK2 1205/4885MAP4K4 28/4885MAP3K12 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.